

CADTH RAPID RESPONSE REPORT:
SUMMARY WITH CRITICAL APPRAISAL

Blue Light Cystoscopy in Patients with Suspected Non-Muscle Invasive Bladder Carcinoma: A Review of Clinical Utility

Service Line: Rapid Response Service
Version: 1.0
Publication Date: February 15, 2017
Report Length: 15 Pages

Authors: Khai Tran, Melissa Severn

Cite As: Blue Light Cystoscopy in Patients with Suspected Non-Muscle Invasive Bladder Carcinoma: A Review of Clinical Utility. Ottawa: CADTH; 2017 Feb. (CADTH rapid response report: summary with critical appraisal).

ISSN: 1922-8147 (online)

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Context and Policy Issues

According to Canadian Cancer Statistics, bladder cancer is the fifth most common cancer, accounting for more than 4% of all cancers or 7,800 cases per year.¹ Of all incidents of bladder cancer cases at first diagnosis, about 80% were non-muscle invasive bladder cancer (NMIBC) and 20% were muscle invasive and advanced bladder cancer.² Smoking is the main risk factor of bladder cancer.^{2,3} Other risk factors include exposure to chemicals such as aromatic compounds, radiation and chemotherapy.^{2,3} The most common symptom of bladder cancer is the presence of blood in the urine.² Bladder cancer is diagnosed by means of cystoscopy and transurethral resection of the bladder tumor (TURBT) in combination with urine analysis and cytology.^{2,4} The tumors are classified based on the degree of invasion into layers of tissues; CIS (flat on surface or carcinoma in situ), Ta (raspberry growth on surface), and T1 (moves into submucosa layer) are those not yet invading into the muscle or NMIBC, while T2a, T2b, T3b and T4a are those invade deeper into the muscle layer and perivesical fat tissue.² About 60% of NMIBC are Ta type, while CIS and T1 account for 10% and 30%, respectively.³ After the initial removal of NMIBC by TURBT, tumors can come back (recurrence) or come back and invade into the muscle layer (progression).² Tumors are graded based on the risk of progression and metastasis.³ For instance, Ta tumors are usually low grade (non-aggressive) but have high risk of recurrence and just require repeated scraping, while CIS and T1 tumors are high grade (aggressive), have a high risk of progression to muscle layer and require more aggressive treatment.²

Visibility of tumors is very important during TURBT, in particular flat lesions such as CIS or low-graded tumors are often missed under standard white light cystoscopy.⁵ A new technique termed “blue light” cystoscopy have been introduced to improve the visibility of tumors by using a photosensitizing agent and fluorescent light in the photodynamic diagnosis of NMIBC.⁴ In fluorescent cystoscopy, the photosensitizing agent such as 5-aminolevulinic acid (5-ALA) or hexaminolevulinatate (HAL), a derivative of 5-ALA, are first instilled into the bladder.⁴ The drug then incorporates into the urothelial cytoplasm where abnormal cells appear red and normal cells appear blue green upon illumination with fluorescent light.⁴ Thus, “blue light” or fluorescent cystoscopy may help the detection of tumors more accurately and may reduce the risk of recurrence and progression compared to white light cystoscopy. HAL needs a much shorter instillation time than 5-ALA and has been approved only for detection of bladder cancer in Europe and USA since 2010.⁴ HAL, branded as Cysview, has been approved by Health Canada since November 2015 as an adjunct to cystoscopy for the detection of NMIBC in patients with known or suspicion of bladder cancer.^{6,7}

The aim of this report is to review the clinical utility of “blue light” cystoscopy in patients with suspected NMIBC undergoing TURBT.

Research Question

What is the clinical utility of blue light cystoscopy in patients with suspected NMIBC undergoing TURBT?

Key Findings

Hexaminolevulinate-guided transurethral resection of bladder tumors was associated with a decreased risk of bladder cancer recurrence and a decreased risk of progression to muscle invasive bladder cancer compared to white light cystoscopy. Evidence on mortality and harms was inconclusive due to sparse data.

Methods

Literature Search Methods

A limited literature search was conducted on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. The search was limited to English language documents published between Jan 1, 2012 and Jan 13, 2017.

Selection Criteria and Methods

One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

Exclusion Criteria

Studies were excluded if they did not satisfy the selection criteria in Table 1, and if they were published prior to 2012. Conference abstracts, duplicates of publication of the same study, or SRs in which their included studies were reviewed in an more recent or more comprehensive SR were excluded.

Table 1: Selection Criteria

Population	Patients suspected of non-muscle invasive bladder carcinoma undergoing transurethral resection of bladder tumor (TURBT)
Intervention	Hexaminolevulinate (HAL)- or 5-aminolevulinic acid (5-ALA)-guided blue light cystoscopy (also referred to as fluorescent cystoscopy)
Comparator	White-light cystoscopy
Outcomes	Clinical utility outcomes (e.g., removal, resection quality, rate of recurrence [short and long term], mortality, disease progression)
Study Designs	Health technology assessments (HTAs), systematic reviews (SRs), or meta-analyses (MAs)

Critical Appraisal of Individual Studies

The SIGN checklist for systematic reviews and meta-analyses were used to assess the quality of SRs and MAs.⁸

Summary of Evidence

Quantity of Research Available

A total of 223 citations were identified in the literature search. Following screening of titles and abstracts, 211 citations were excluded and 12 potentially relevant reports from the electronic search were retrieved for full-text review. No potentially relevant publications were retrieved from the grey literature search. Of these potentially relevant articles, 10 publications were excluded for various reasons, while 2 publications met the inclusion criteria and were included in this report. Appendix 1 describes the PRISMA flowchart of the study selection.

Additional references of potential interest are provided in Appendix 5.

Summary of Study Characteristics

The characteristics of the SRs and MAs^{9,10} are briefly described below and detailed in Appendix 2.

Country of Origin

The studies were conducted by authors from the USA⁹ and Germany and Malaysia.¹⁰ They were all published in 2016.

Search Methods and Results of Study Selection

Searches were conducted in multiple databases (January 1990 to October 2014)⁹ or from a single database (between 2000 and 2016)¹⁰ with restriction to English language only.^{9,10} One SR⁹ selected only RCTs, while the other SR¹⁰ included RCTs and observational studies.

Patient Population

Most of the included studies in both SRs^{9,10} had mixed populations including those with new diagnoses of bladder cancer, those with high risk bladder cancer, and those of mixed conditions who had initial or recurrent bladder cancer. The mean age of patients was reported in one SR and ranged from 60 to 74 years. Patients were predominantly male.⁹

Interventions and Comparators

Both SRs included studies comparing fluorescent light cystoscopy with white light cystoscopy.^{9,10} One SR⁹ included studies that used 5-ALA or HAL, while the other SR¹⁰ included studies that used only HAL as the photosensitizing agent.

Outcomes

The clinical outcomes included recurrence,⁹ progression,^{9,10} mortality,⁹ and harms.⁹

Follow-up Period

Follow-up period of the included studies ranged from four weeks to 60 months in one SR⁹ and from one to 55 months in the other SR.¹⁰ Follow-up was reserved for NMIBC patients of stage Ta, T1 or CIS on initial cystoscopy.⁹

Data Analysis and Synthesis

Data were analyzed was a meta-analysis approach and the statistical heterogeneity was described using the *p* value for the Q test and the I^2 test.^{9,10} In one SR,⁹ the recurrence was stratified according to the duration of follow-up as short-term (<3 months), intermediate-term (3 months to <1 year) or long-term (≥1 year). Publication bias was investigated using funnel plots.^{9,10}

Study Appraisal

The Cochrane risk of bias tool was used by two SRs^{9,10} to assess the methodological quality of included studies, and the strength of evidence for each body of evidence in one SR⁹ was assessed based on study quality, precision, consistency and directness.

Summary of Critical Appraisal

The summary of the quality assessment for the SRs are presented below and in Appendix 3.

One SR⁹ was of high quality as most of the criteria were fulfilled, including an explicit research question, a comprehensive literature search, at least two people involved in the study selection and data extraction, a description of the relevant characteristics of the included studies, a quality assessment of included studies, appropriate methods of meta-analysis, appropriate assessment of the likelihood of publication bias, and a declaration of potential conflicts of interest. Potential publication bias was detected in both systematic reviews.^{9,10} The other SR¹⁰ was of moderate quality as some of the criteria were not fulfilled or not clearly described such as a comprehensive literature search, multiple people involved in study selection, relevant characteristics of the included studies and appropriate methods of combining the individual study findings. The SR¹⁰ was, however, explicit in terms of clearly defined research question, two people involving in data extraction, quality assessment of included studies, assessment of publication bias and declaration of conflict of interest. Neither SR provided a list of excluded studies.^{9,10}

Summary of Findings

What is the clinical utility of blue light cystoscopy in patients with suspected NMIBC undergoing TURBT?

Meta-analysis was conducted for clinical outcomes including recurrence,⁹ progression,^{9,10} and mortality.⁹ Harms were assessed by detection of local adverse events.⁹ Appendix 4 presents main findings of the included SRs.

Recurrence

For the detection and resection of NMIBC with TURBT, fluorescent cystoscopy was associated with a statistically significantly reduced risk of bladder cancer recurrence compared with white light cystoscopy at short-term (evidence from 10 RCTs) and long-term follow-up (evidence from 12 RCTs).⁹ Stratifying analysis by photosensitizer showed that the effects were statistically significant in trials using HAL, but not in trials using 5-ALA. However, the point estimates were similar and there were no statistically significant interactions based on photosensitizer (p for interaction = 0.97 for short-term or 0.41 for long-term).⁹ Statistical heterogeneity remained in both subgroups.⁹ The strength of evidence was low due to risk of performance or publication bias.⁹

Progression

A pooled analysis of all trials using 5-ALA or HAL showed no difference between fluorescent cystoscopy compared with white light cystoscopy in the risk of progression to muscle invasive bladder cancer.⁹ Subgroup analysis showed that the risk of progression was statistically significantly lower in trials using HAL,⁹ but not in trials using 5-ALA.⁹ However, subgroup effect was not statistically significant (p for interaction = 0.18).⁹ The strength of the evidence was moderate.⁹ The other SR also found that HAL-guided TURBT was associated with statistically significant reduction in the risk of progression compared to white light guided TURBT.¹⁰

Mortality

There was no difference in mortality between fluorescent cystoscopy and white light cystoscopy in trials using 5-ALA or HAL.⁹ The strength of the evidence was low due to imprecision and sparse data.

Harms

There was no difference between fluorescent cystoscopy and white light cystoscopy for local adverse events such as hematuria, dysuria, urinary frequency or urgency and bladder spasms occurred after cystoscopy.⁹ Data on harms were sparse.

Limitations

One SR⁹ reported that there were substantial statistical heterogeneities in some pooled analyses of recurrence, despite the stratification of the effects by follow-up intervals. The effects at short-term and long-term recurrence were inconsistent across trials. The same SR also found that, in three trials, when methods were used to reduce performance bias, fluorescent cystoscopy using HAL was not associated with decreasing long-term recurrence.⁹ Funnel plots for trials investigating short-term recurrence⁹ or progression¹⁰ suggested that there was potential publication bias. The strength of the evidence was therefore low as there was a risk of performance or publication bias. In addition, there was insufficient evidence to understand the benefit of fluorescent cystoscopy in patients with different risks of NMIBC or with different tumor characteristics (i.e. grade, multiplicity, or primary versus recurrent). Follow-up periods were not long enough to better understand the effects of fluorescent cystoscopy on progression and mortality. No survival data could be identified.


Conclusions and Implications for Decision or Policy Making

Low to moderate quality evidence from recent SRs has suggested that TURBT guided by fluorescent or “blue light” cystoscopy using HAL as photosensitizing agent in the detection and resection of NMIBC was associated with a decreased risk of bladder cancer recurrence and a decreased risk of progression to muscle invasive bladder cancer compared to white light cystoscopy. The effects on recurrence and progression were not statistically significant in trials that used 5-ALA. The effects of fluorescent cystoscopy on mortality were inconclusive due to sparse data. More studies are needed with better study designs and longer term follow-up to understand the impact of HAL-based TURBT on recurrence, progression and survival in patients with different NMIBC risks, different tumor grading systems and different treatment strategies.

References

1. Canadian cancer statistics. Special topic: HPV-associated cancers [Internet]. Toronto: Canadian Cancer Society; 2016. [cited 2017 Jan 23]. Available from: <http://www.cancer.ca/~media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2016-EN.pdf>
2. Morash C. Non-muscle invasive bladder cancer [slide deck]. Ottawa: Bladder Cancer Canada; 2013 Nov 18.
3. Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, et al. CUA guidelines on the management of non-muscle invasive bladder cancer. *Can Urol Assoc J* [Internet]. 2015 Sep [cited 2017 Jan 23];9(9-10):E690-E704. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662433>
4. Oude Elferink P, Witjes JA. Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. *Ther Adv Urol* [Internet]. 2014 Feb [cited 2017 Jan 18];6(1):25-33. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891293>
5. Mark JR, Gelpi-Hammerschmidt F, Trabulsi EJ, Gomella LG. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. *Can J Urol* [Internet]. 2012 Apr [cited 2017 Jan 18];19(2):6227-31. Available from: http://www.canjurol.com/html/free-articles/V19I2-19_DrMark.pdf
6. ^{Pr}Cysview™: hexaminolevulinate hydrochloride powder for intravesical solution, 100 mg/vial [product monograph on the Internet]. Toronto (ON): BioSyent Pharma Inc.; 2015 Oct 16. [cited 2017 Jan 30]. Available from: [http://www.cysview.ca/files/Cysview%20Canada%20PM%20\(EN%20-%20October%2016,%202015\).pdf](http://www.cysview.ca/files/Cysview%20Canada%20PM%20(EN%20-%20October%2016,%202015).pdf)
7. Press release, BioSyent Pharma announces the Canadian launch of CYSVIEW® (hexaminolevulinate hydrochloride) [Internet]. Toronto (ON): Marketwired; 2015 Nov 17. [cited 2017 Jan 30]. Available from: <http://www.marketwired.com/press-release/biosyent-pharma-announces-canadian-launch-cysviewr-hexaminolevulinate-hydrochloride-tsx-venture-rx-2074401.htm>
8. Methodology checklist 1: systematic reviews and meta-analyses [Internet]. Edinburgh, United Kingdom: Scottish Intercollegiate Guidelines Network; 2017. [cited 2017 Jan 23]. Available from: <http://www.sign.ac.uk/pdf/sign50annexc.pdf>
9. Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S, et al. Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: systematic review and meta-analysis. *J Urol*. 2016 Oct 22. Epub ahead of print.
10. Gakis G, Fahmy O. Systematic review and meta-analysis on the impact of hexaminolevulinate- versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer. *Bladder Cancer* [Internet]. 2016 Jul 27 [cited 2017 Jan 18];2(3):293-300. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969683>

Appendix 1: Selection of Included Studies



Appendix 2: Characteristics of Included Systematic Reviews and Meta-analyses

Study, Year, Country, Design, and Quality Assessment Tool, Funding	Electronic searches, and Search Range	Included Studies: Types, Numbers, Publication Year, Follow-up	Population: Number, conditions	Intervention and Control Groups (No. of study)	Subgroup or Meta-regression Analysis	Outcomes (No. of study)
<p>Chou et al., 2016⁹</p> <p>USA</p> <p>SR and MA</p> <p>Risk of Bias developed by the US Preventive Services Task Force</p> <p>Agency for Healthcare Research and Quality (AHRQ)</p> <p>Strength of evidence graded using AHRQ methods</p>	<p>MEDLINE (Jan 1990 to Oct 2014), Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through Sep 2014), ClinicalTrials.gov; restricted to English language</p> <p>Updated in Sep 2015</p>	<p>14 RCTs</p> <p>2001 to 2014</p> <p>Follow-up: 4 weeks to 60 months using fluorescent cystoscopy (3 RCTs) or using white light cystoscopy (11 RCTs)</p> <p>Follow-up was for patients with NMIBC (Ta, Ti and in some cases CIS) on initial cystoscopy: range from 4 weeks to 60 months</p>	<p>2,906 patients (range 44 to 551 patients)</p> <p>Mean age: 60 to 74 years</p> <p>Gender: predominantly male (ratio not reported)</p> <p>New bladder cancer (2 RCTs), high risk bladder cancer (2 RCTs), mixed conditions (10 RCTs)</p>	<p>Intervention: ALA fluorescent light cystoscopy with TURBT (6 RCTs)</p> <p>HAL fluorescent light cystoscopy with TURBT (9 RCTs)</p> <p>Control: White light cystoscopy with TURBT</p>	<p>By photosensitizing agent</p>	<ul style="list-style-type: none"> • Recurrence^a (10 RCTs) • Progression^b (9 RCTs) • Mortality (3 RCTs) • Harms (3 RCTs)
<p>Gakis and Fahmy, 2016¹⁰</p> <p>Germany and Malaysia</p> <p>Cochrane risk of bias for RCTs and Newcastle-Ottawa scale for retrospective studies</p> <p>Funding: NR</p>	<p>Pubmed and hand search; restricted to English language</p> <p>2000 to 2016</p>	<p>4 RCTs and 1 retrospective study</p> <p>2009 to 2016</p> <p>Follow-up: 1 to 55 months</p>	<p>1,301 patients (range 44 to 516)</p> <p>Mean age: NR</p> <p>Patients with NMIBC</p>	<p>HAL fluorescent light cystoscopy with TURBT (5 studies)</p> <p>Control: White light cystoscopy with TURBT</p>	<p>No</p>	<ul style="list-style-type: none"> • Progression^b (5 studies)

ALA = 5-aminolevulinic acid; CIS = carcinoma in situ; HAL = hexaminolevulinic acid; MA = meta-analysis; NMIBC = non-muscle invasive bladder cancer; NR = not reported; RCT = randomized controlled trial; SR = systematic review; TURBT = transurethral bladder tumor resection; vs = versus

^aRecurrence: short-term (less than 3 months), intermediate-term (3 months to less than 1 year), long-term (1 year or more) after initial cystoscopy

^bProgression to muscle invasive bladder cancer

Appendix 3: Quality Assessment of Systematic Reviews and Meta-analyses

SIGN checklist: Internal Validity	Chou et al., 2016⁹	Gakis and Fahmy, 2016¹⁰
1. The research question is clearly defined and the inclusion/exclusion criteria must be listed in the paper	Yes	Yes
2. A comprehensive literature search is carried out	Yes	No
3. At least two people should have selected studies	Yes	Can't tell
4. At least two people should have extracted data	Yes	Yes
5. The status of publication was not used as an inclusion criteria	Yes	Yes
6. The excluded studies are listed	No	No
7. The relevant characteristics of the included studies are provided	Yes	Not clear
8. The scientific quality of the included studies was assessed and reported	Yes	Yes
9. Was the scientific quality of the included studies used appropriately?	Yes	Yes
10. Appropriate methods are used to combine the individual study findings	Yes	No
11. The likelihood of publication bias was assessed appropriately	Yes	Yes
12. Conflicts of interest are declared	Yes	Yes
Overall Assessment of the Study		
High, Moderate, Low	High	Moderate

For overall assessment of the study: *High* indicated that all or most criteria have been fulfilled; where they have not been fulfilled, the conclusions of the study or review are thought very unlikely to alter. *Moderate* indicates that some of the criteria have been fulfilled; those criteria that have not been fulfilled or not adequately described are thought unlikely to alter the conclusions. *Low* indicates that few or no criteria fulfilled; the conclusions of the study are thought likely or very likely to alter.

Appendix 4: Main Study Findings and Author’s Conclusions

Study, Year, Country, Design	Main Findings																																																																																																									
Chou et al., 2016⁹ USA SR and MA	<p>Risk of bias: High (4 RCTs) Medium (11 RCTs)</p> <p>Recurrence – Short term (<3 months)</p> <table border="1"> <thead> <tr> <th>Intervention</th> <th>No. studies</th> <th>RR (95% CI)</th> <th>I²</th> <th>Strength of evidence</th> </tr> </thead> <tbody> <tr> <td>Overall</td> <td>10</td> <td>0.60 (0.37 to 0.88)</td> <td>67%</td> <td>Low</td> </tr> <tr> <td>ALA</td> <td>4</td> <td>0.57 (0.28 to 1.16)</td> <td>84%</td> <td></td> </tr> <tr> <td>HAL</td> <td>6</td> <td>0.62 (0.38 to 1.00)</td> <td>51%</td> <td></td> </tr> </tbody> </table> <p>Recurrence – Intermediate term (3 months to <12 months)</p> <table border="1"> <thead> <tr> <th>Intervention</th> <th>No. studies</th> <th>RR (95% CI)</th> <th>I²</th> <th>Strength of evidence</th> </tr> </thead> <tbody> <tr> <td>Overall</td> <td>6</td> <td>0.70 (0.56 to 0.88)</td> <td>19%</td> <td>Low</td> </tr> <tr> <td>ALA</td> <td>1</td> <td>0.56 (0.34 to 0.91)</td> <td>NA</td> <td></td> </tr> <tr> <td>HAL</td> <td>5</td> <td>0.76 (0.62 to 0.93)</td> <td>7%</td> <td></td> </tr> </tbody> </table> <p>Recurrence – Long term (≥12 months)</p> <table border="1"> <thead> <tr> <th>Intervention</th> <th>No. studies</th> <th>RR (95% CI)</th> <th>I²</th> <th>Strength of evidence</th> </tr> </thead> <tbody> <tr> <td>Overall</td> <td>12</td> <td>0.81 (0.70 to 0.93)</td> <td>46%</td> <td>Low</td> </tr> <tr> <td>ALA</td> <td>5</td> <td>0.86 (0.68 to 1.08)</td> <td>66%</td> <td></td> </tr> <tr> <td>HAL</td> <td>7</td> <td>0.75 (0.62 to 0.92)</td> <td>41%</td> <td></td> </tr> <tr> <td></td> <td>3 (where performance bias was reduced)</td> <td>0.96 (0.79 to 1.18)</td> <td>36%</td> <td></td> </tr> </tbody> </table> <p>Progression to muscle invasive bladder cancer</p> <table border="1"> <thead> <tr> <th>Intervention</th> <th>No. studies</th> <th>RR (95% CI)</th> <th>I²</th> <th>Strength of evidence</th> </tr> </thead> <tbody> <tr> <td>Overall</td> <td>9</td> <td>0.74 (0.52 to 1.03)</td> <td>0%</td> <td>Moderate</td> </tr> <tr> <td>ALA</td> <td>5</td> <td>0.86 (0.57 to 1.28)</td> <td>0%</td> <td></td> </tr> <tr> <td>HAL</td> <td>4</td> <td>0.51 (0.28 to 0.96)</td> <td>0%</td> <td></td> </tr> </tbody> </table> <p>Mortality</p> <table border="1"> <thead> <tr> <th>Intervention</th> <th>No. studies</th> <th>RR (95% CI)</th> <th>I²</th> <th>Strength of evidence</th> </tr> </thead> <tbody> <tr> <td>Overall</td> <td>3</td> <td>1.28 (0.55 to 2.95)</td> <td>43%</td> <td>Low</td> </tr> <tr> <td>ALA</td> <td>1</td> <td>1.22 (0.34 to 4.46)</td> <td>NA</td> <td></td> </tr> <tr> <td>HAL</td> <td>2</td> <td>1.87 (0.29 to 12.22)</td> <td>71%</td> <td></td> </tr> </tbody> </table> <p>Harms: No difference between fluorescent cystoscopy and white light cystoscopy for local adverse events such as hematuria, dysuria, urinary frequency or urgency and bladder spasms occurred after cystoscopy (the frequency of events was not reported).</p> <p>Authors’ conclusions: “Fluorescent cystoscopy was associated with a reduced risk of recurrence vs white light cystoscopy, although there were inconsistencies and our findings may have been affected by performance bias or publication bias. Fluorescent cystoscopy with HAL may be associated with a decreased risk of progression but more studies with long-term follow-up are needed to better understand the effects of photosensitizer used on progression. Evidence on the effects of fluorescent cystoscopy on mortality is too sparse to reach strong conclusions.”⁹ p.9</p>	Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence	Overall	10	0.60 (0.37 to 0.88)	67%	Low	ALA	4	0.57 (0.28 to 1.16)	84%		HAL	6	0.62 (0.38 to 1.00)	51%		Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence	Overall	6	0.70 (0.56 to 0.88)	19%	Low	ALA	1	0.56 (0.34 to 0.91)	NA		HAL	5	0.76 (0.62 to 0.93)	7%		Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence	Overall	12	0.81 (0.70 to 0.93)	46%	Low	ALA	5	0.86 (0.68 to 1.08)	66%		HAL	7	0.75 (0.62 to 0.92)	41%			3 (where performance bias was reduced)	0.96 (0.79 to 1.18)	36%		Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence	Overall	9	0.74 (0.52 to 1.03)	0%	Moderate	ALA	5	0.86 (0.57 to 1.28)	0%		HAL	4	0.51 (0.28 to 0.96)	0%		Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence	Overall	3	1.28 (0.55 to 2.95)	43%	Low	ALA	1	1.22 (0.34 to 4.46)	NA		HAL	2	1.87 (0.29 to 12.22)	71%	
Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence																																																																																																						
Overall	10	0.60 (0.37 to 0.88)	67%	Low																																																																																																						
ALA	4	0.57 (0.28 to 1.16)	84%																																																																																																							
HAL	6	0.62 (0.38 to 1.00)	51%																																																																																																							
Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence																																																																																																						
Overall	6	0.70 (0.56 to 0.88)	19%	Low																																																																																																						
ALA	1	0.56 (0.34 to 0.91)	NA																																																																																																							
HAL	5	0.76 (0.62 to 0.93)	7%																																																																																																							
Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence																																																																																																						
Overall	12	0.81 (0.70 to 0.93)	46%	Low																																																																																																						
ALA	5	0.86 (0.68 to 1.08)	66%																																																																																																							
HAL	7	0.75 (0.62 to 0.92)	41%																																																																																																							
	3 (where performance bias was reduced)	0.96 (0.79 to 1.18)	36%																																																																																																							
Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence																																																																																																						
Overall	9	0.74 (0.52 to 1.03)	0%	Moderate																																																																																																						
ALA	5	0.86 (0.57 to 1.28)	0%																																																																																																							
HAL	4	0.51 (0.28 to 0.96)	0%																																																																																																							
Intervention	No. studies	RR (95% CI)	I ²	Strength of evidence																																																																																																						
Overall	3	1.28 (0.55 to 2.95)	43%	Low																																																																																																						
ALA	1	1.22 (0.34 to 4.46)	NA																																																																																																							
HAL	2	1.87 (0.29 to 12.22)	71%																																																																																																							

Study, Year, Country, Design	Main Findings														
Gakis and Fahmy, 2016¹⁰ Germany and Malaysia SR and MA	Risk of bias: low to moderate Progression to muscle invasive bladder cancer <table border="1" data-bbox="391 478 1450 569"> <thead> <tr> <th data-bbox="391 478 565 537">Intervention</th> <th data-bbox="565 478 711 537">No. studies</th> <th data-bbox="711 478 938 537">%WL-TURBT vs % HAL-TURBT</th> <th data-bbox="938 478 1312 537">OR (95% CI)</th> <th data-bbox="1312 478 1450 537"><i>I</i>²</th> </tr> </thead> <tbody> <tr> <td data-bbox="391 537 565 569">HAL</td> <td data-bbox="565 537 711 569">5</td> <td data-bbox="711 537 938 569">10.7 vs 6.8</td> <td data-bbox="938 537 1312 569">1.64 (0.28 to 0.96)</td> <td data-bbox="1312 537 1450 569">0%</td> </tr> </tbody> </table>					Intervention	No. studies	%WL-TURBT vs % HAL-TURBT	OR (95% CI)	<i>I</i> ²	HAL	5	10.7 vs 6.8	1.64 (0.28 to 0.96)	0%
Intervention	No. studies	%WL-TURBT vs % HAL-TURBT	OR (95% CI)	<i>I</i> ²											
HAL	5	10.7 vs 6.8	1.64 (0.28 to 0.96)	0%											
Authors' conclusions: "This meta-analysis supported the assumption that the detection and resection of NMIBC with HAL-guided TURBT reduces the risk of progression. Therefore, patients should receive hexaminolevulinate- rather than white-light-guided TURBT at their first resection as this might allow more patients at risk of progression to be treated timely and adequately." ¹⁰ p.299															

ALA = 5-aminolevulinic acid; CI = confidence interval; HAL = hexaminolevulinic acid; MA = meta-analysis; NA = not applicable; NMIBC = non-muscle invasive bladder cancer; RCT = randomized controlled trial; RR = relative risk; SR = systematic review; TURBT = transurethral bladder tumor resection; vs = versus; WL = white light

Appendix 5: Additional References of Potential Interest

The following SRs overlapped with the included SR by Chou et al, 2016.⁹

Chou R, Buckley D, Fu R, Gore JL, Gustafson K, Griffin J, et al. Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Oct. [cited 2017 Jan 18]. (AHRQ Comparative Effectiveness Reviews). Available from: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0080825/pdf/PubMedHealth_PMH0080825.pdf

Di Stasi SM, De CF, Pagliarulo V, Masedu F, Verri C, Celestino F, et al. Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder. *Ther Adv Urol* [Internet]. 2015 Dec [cited 2017 Jan 18];7(6):339-50. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647142>

Yuan H, Qiu J, Liu L, Zheng S, Yang L, Liu Z, et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. *PLoS ONE* [Internet]. 2013 [cited 2017 Jan 18];8(9):e74142. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772837>

Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. *Eur Urol*. 2013 Oct;64(4):624-38.

Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. *Eur Urol*. 2013 Nov;64(5):846-54.